KRFK

• UNSPSC Description:

  KRFK, a peptide derived from TSP-1, can activate TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach[1].

• Target Antigen:

  TGF-β Receptor

• Type:

  Peptides

• Related Pathways:

  TGF-beta/Smad

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/krfk.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCCN)C(O)=O)=O)=O)[C@H](CCCCN)N

• Molecular Weight:

  577.72

• References & Citations:

  [1]Soriano-Romaní L, et al. Topical Application of TGF-β-Activating Peptide, KRFK, Prevents Inflammatory Manifestations in the TSP-1-Deficient Mouse Model of Chronic Ocular Inflammation. Int J Mol Sci. 2018 Dec 20;20(1):9.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  162290-78-0